105 related articles for article (PubMed ID: 22360509)
1. Phyllodes tumor of the prostate.
Fujii T; Shimada K; Tanaka N; Fujimoto K; Konishi N
Pathol Int; 2012 Mar; 62(3):204-8. PubMed ID: 22360509
[TBL] [Abstract][Full Text] [Related]
2. Phyllodes tumor of the prostate: long-term followup study of 23 cases.
Bostwick DG; Hossain D; Qian J; Neumann RM; Yang P; Young RH; di Sant'agnese PA; Jones EC
J Urol; 2004 Sep; 172(3):894-9. PubMed ID: 15310992
[TBL] [Abstract][Full Text] [Related]
3. Phyllodes tumor of the prostate: a case report.
Ito H; Ito M; Mitsuhata N; Tahara E
Jpn J Clin Oncol; 1989 Sep; 19(3):299-304. PubMed ID: 2478740
[TBL] [Abstract][Full Text] [Related]
4. Phyllodes tumor of the seminal vesicle: case report and literature review.
Son HJ; Jeong YJ; Kim JH; Chung MJ
Pathol Int; 2004 Dec; 54(12):924-9. PubMed ID: 15598315
[TBL] [Abstract][Full Text] [Related]
5. [Prostatic phyllodes tumor, a rare entity. Anatamo-clinical and immunohistochemical study of 1 case].
Chatelain D; Coppola S; De Pinieux G ; David E; Viellefond A
Ann Pathol; 2000 Dec; 20(6):629-32. PubMed ID: 11148362
[TBL] [Abstract][Full Text] [Related]
6. Giant cystosarcoma phyllodes tumor of prostate: case report of a rare entity.
Bhat DM; Poflee SV; Kotwal MN; Pangarkar MA; Gadkari RU; Bobhate SK
Indian J Cancer; 2004; 41(3):129-32. PubMed ID: 15472412
[TBL] [Abstract][Full Text] [Related]
7. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
8. Phyllodes tumor of the prostate with exuberant glandular hyperplasia.
Morikawa T; Nagata M; Tomita K; Kitamura T; Goto A; Chong JM; Fukayama M
Pathol Int; 2006 Mar; 56(3):158-61. PubMed ID: 16497250
[TBL] [Abstract][Full Text] [Related]
9. Can perineural invasion on prostate needle biopsy predict prostate specific antigen recurrence after radical prostatectomy?
de la Taille A; Rubin MA; Bagiella E; Olsson CA; Buttyan R; Burchardt T; Knight C; O'Toole KM; Katz AE
J Urol; 1999 Jul; 162(1):103-6. PubMed ID: 10379750
[TBL] [Abstract][Full Text] [Related]
10. Phyllodes tumor of the prostate: recurrent obstructive symptom and stromal proliferative activity.
Shiraishi K; Mohri J; Eguchi S; Kamiryo Y; Sanefuji H
Int J Urol; 2004 Sep; 11(9):801-4. PubMed ID: 15379951
[TBL] [Abstract][Full Text] [Related]
11. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
12. Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease.
Freedland SJ; Mangold LA; Epstein JI; Partin AW
Urology; 2004 May; 63(5):887-91. PubMed ID: 15134972
[TBL] [Abstract][Full Text] [Related]
13. [A case of ductal carcinoma of the prostate after transurethral resection of prostate].
Izumi K; Kanno H; Umemoto S; Hasumi H; Osada Y; Ota J; Tsuchiya F; Ogino I; Harada M
Hinyokika Kiyo; 2007 May; 53(5):315-8. PubMed ID: 17561717
[TBL] [Abstract][Full Text] [Related]
14. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Kupelian P; Katcher J; Levin H; Zippe C; Klein E
Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
[TBL] [Abstract][Full Text] [Related]
15. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
16. Malignant phyllodes tumor of the prostate.
Wu YS; Lee SH; Shen BY; Chang PL; Tsui KH; Ng KF
Arch Androl; 2005; 51(4):295-8. PubMed ID: 16036637
[TBL] [Abstract][Full Text] [Related]
17. [A case report of prostatic stromal tumor of uncertain malignant potential (STUMP)].
Fukuhara S; Matsuoka Y; Hanafusa T; Nakayama M; Takayama H; Tsujihata M; Nonomura N; Okuyama A
Hinyokika Kiyo; 2008 May; 54(5):377-81. PubMed ID: 18546866
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
Giesing M; Suchy B; Driesel G; Molitor D
BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
[TBL] [Abstract][Full Text] [Related]
19. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
20. [Characteristics of prostatic cancer in men with a serum prostate-specific antigen level of < or =4.0 ng/ml].
Ono Y; Chiba K; Tanaka H
Hinyokika Kiyo; 2005 Oct; 51(10):647-50. PubMed ID: 16285616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
